Cargando…

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa, Kadam, Manoj, Kumar, Abhimanyu, Majumdar, Triparna, Jain, Rajlaxmi, Deshpande, Gururaj, Patil, Savita, Sarkale, Prasad, Patil, Deepak, Ella, Raches, Prasad, Sai D., Sharma, Sharda, Ella, Krishna M., Panda, Samiran, Bhargava, Balram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/
https://www.ncbi.nlm.nih.gov/pubmed/33521604
http://dx.doi.org/10.1016/j.isci.2021.102054
Descripción
Sumario:The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.